Stephen W Patrick1, Robert E Schumacher2, Jeffrey D Horbar3, Madge E Buus-Frank4, Erika M Edwards5, Kate A Morrow6, Karla R Ferrelli6, Alan P Picarillo7, Munish Gupta8, Roger F Soll3. 1. Departments of Pediatrics, Health Policy, and Mildred Stahlman Division of Neonatology, Vanderbilt University, Nashville, Tennessee; Vanderbilt Center for Health Services Research, Nashville, Tennessee; stephen.patrick@vanderbilt.edu. 2. Department of Pediatrics, University of Michigan Health System, Ann Arbor, Michigan; 3. Vermont Oxford Network, Burlington, Vermont; Departments of Pediatrics, and. 4. Vermont Oxford Network, Burlington, Vermont; Departments of Pediatrics, and Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; 5. Vermont Oxford Network, Burlington, Vermont; Mathematics and Statistics, University of Vermont, Burlington, Vermont; 6. Vermont Oxford Network, Burlington, Vermont; 7. Division of Neonatology, University of Massachusetts Medical School, Worcester, Massachusetts; Neonatal Quality Improvement Collaborative of Massachusetts, Boston, Massachusetts; 8. Neonatal Quality Improvement Collaborative of Massachusetts, Boston, Massachusetts; Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND AND OBJECTIVE: Care for neonatal abstinence syndrome (NAS), a postnatal drug withdrawal syndrome, remains variable. We designed and implemented a multicenter quality improvement collaborative for infants with NAS. Our objective was to determine if the collaborative was effective in standardizing hospital policies and improving patient outcomes. METHODS: From 2012 to 2014, data were collected through serial cross-sectional audits of participating centers. Hospitals assessed institutional policies and patient-level data for infants with NAS requiring pharmacotherapy, including length of pharmacologic treatment and length of hospital stay (LOS). Models were fit, clustered according to hospital, to evaluate changes in patient outcomes over time. RESULTS: Among 199 participating centers, the mean number of NAS-focused guidelines increased from 3.7 to 5.1 of a possible 6 (P < .001), with improvements noted in all measured domains. Among infants cared for at participating centers, decreases occurred in median (interquartile range) length of pharmacologic treatment, from 16 days (10 to 27 days) to 15 days (10 to 24 days; P = .02), and LOS from 21 days (14 to 33 days) to 19 days (15 to 28 days; P = .002). In addition, there was a statistically significant decrease in the proportion of infants discharged on medication for NAS, from 39.7% to 26.5% (P = .02). After adjusting for potential confounders, standardized NAS scoring process was associated with shorter LOS (-3.3 days,95% confidence interval, -4.9 to -1.4). CONCLUSIONS: Involvement in a multicenter, multistate quality improvement collaborative focused on infants requiring pharmacologic treatment for NAS was associated with increases in standardizing hospital patient care policies and decreases in health care utilization.
BACKGROUND AND OBJECTIVE: Care for neonatal abstinence syndrome (NAS), a postnatal drug withdrawal syndrome, remains variable. We designed and implemented a multicenter quality improvement collaborative for infants with NAS. Our objective was to determine if the collaborative was effective in standardizing hospital policies and improving patient outcomes. METHODS: From 2012 to 2014, data were collected through serial cross-sectional audits of participating centers. Hospitals assessed institutional policies and patient-level data for infants with NAS requiring pharmacotherapy, including length of pharmacologic treatment and length of hospital stay (LOS). Models were fit, clustered according to hospital, to evaluate changes in patient outcomes over time. RESULTS: Among 199 participating centers, the mean number of NAS-focused guidelines increased from 3.7 to 5.1 of a possible 6 (P < .001), with improvements noted in all measured domains. Among infants cared for at participating centers, decreases occurred in median (interquartile range) length of pharmacologic treatment, from 16 days (10 to 27 days) to 15 days (10 to 24 days; P = .02), and LOS from 21 days (14 to 33 days) to 19 days (15 to 28 days; P = .002). In addition, there was a statistically significant decrease in the proportion of infants discharged on medication for NAS, from 39.7% to 26.5% (P = .02). After adjusting for potential confounders, standardized NAS scoring process was associated with shorter LOS (-3.3 days,95% confidence interval, -4.9 to -1.4). CONCLUSIONS: Involvement in a multicenter, multistate quality improvement collaborative focused on infants requiring pharmacologic treatment for NAS was associated with increases in standardizing hospital patient care policies and decreases in health care utilization.
Authors: Richard A Epstein; William V Bobo; Peter R Martin; James A Morrow; Wei Wang; Rameela Chandrasekhar; William O Cooper Journal: Ann Epidemiol Date: 2013-08 Impact factor: 3.797
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis Journal: JAMA Date: 2012-04-30 Impact factor: 56.272
Authors: Jennifer N Lind; Emily E Petersen; Philip A Lederer; Ghasi S Phillips-Bell; Cria G Perrine; Ruowei Li; Mark Hudak; Jane A Correia; Andreea A Creanga; William M Sappenfield; John Curran; Carina Blackmore; Sharon M Watkins; Suzanne Anjohrin Journal: MMWR Morb Mortal Wkly Rep Date: 2015-03-06 Impact factor: 17.586
Authors: Michael D Warren; Angela M Miller; Julie Traylor; Audrey Bauer; Stephen W Patrick Journal: MMWR Morb Mortal Wkly Rep Date: 2015-02-13 Impact factor: 17.586
Authors: Jason R Pryor; Faouzi I Maalouf; Elizabeth E Krans; Robert E Schumacher; William O Cooper; Stephen W Patrick Journal: Arch Dis Child Fetal Neonatal Ed Date: 2017-01-10 Impact factor: 5.747
Authors: Jessica N Snowden; A Akshatha; Robert D Annett; Margaret M Crawford; Abhik Das; Lori A Devlin; Rosemary D Higgins; Zhuopei Hu; Elizabeth Lindsay; Stephanie Merhar; Clare Campbell Nesmith; Heather Pratt-Chavez; Judith Ross; Alan E Simon; M Cody Smith; Christine B Turley; Anita Walden; Leslie Young; Bonny Whalen Journal: Hosp Pediatr Date: 2019-07-19
Authors: Timmy Ho; Madge E Buus-Frank; Erika M Edwards; Kate A Morrow; Karla Ferrelli; Arjun Srinivasan; Daniel A Pollock; Dmitry Dukhovny; John A F Zupancic; DeWayne M Pursley; Roger F Soll; Jeffrey D Horbar Journal: Pediatrics Date: 2018-12 Impact factor: 7.124